COVID-19 – Page 7 – Policy & Medicine

FDA COVID-19 Special Emergency Program for Accelerating Research and Development

Managing Pharma and Medical Device Ethics and Compliance Function Remotely

COVID-19 Recent Changes to Telehealth Regulations and Reimbursement

COVID-19 Burden Index Released

COVID-19 Pandemic Compliance Action Plan

Understanding FDA Regulatory Terminology During COVID-19

The Impact COVID-19 is Having on ACOs

CMS Issues Guidances and Suspends Rules to Battle COVID-19

FDA Eases Some Requirements in the COVID-19 Fight

DEA Allows Controlled Substance Prescriptions to Be Issued Via Telemedicine